STOCK TITAN

Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

Terumo Neuro celebrates the 15th anniversary of its WEB™ Aneurysm Embolization System, a revolutionary device that has transformed wide-neck bifurcation aneurysm treatment. Since its CE Mark approval and commercial launch in October 2010, over 25,000 devices have been implanted worldwide.

The WEB device, as the world's first intrasaccular flow disruptor, offers a single-device solution that minimizes the need for dual antiplatelet therapy. Its clinical success is backed by seven global Good Clinical Practice studies and over 200 peer-reviewed publications.

Key achievements include:

  • Zero recorded rebleeds in WEB device-treated aneurysms across 1,464 patient-years
  • 0% device-related morbidity and mortality in five-year follow-up data
  • Introduction of WEB 17 system for treating smaller aneurysms

Terumo Neuro celebra il 15° anniversario del suo WEB™ Aneurysm Embolization System, un dispositivo rivoluzionario che ha trasformato il trattamento degli aneurismi a biforcazione a collo ampio. Dalla sua approvazione CE e dal lancio commerciale nell'ottobre 2010, sono stati impiantati oltre 25.000 dispositivi in tutto il mondo.

Il dispositivo WEB, primo distruttore di flusso intrasacculare al mondo, offre una soluzione con un unico dispositivo che riduce al minimo la necessità di una terapia antipiastrinica duplice. Il suo successo clinico è supportato da sette studi globali di Buona Pratica Clinica e oltre 200 pubblicazioni sottoposte a revisione paritaria.

I risultati chiave includono:

  • Zero rebleeding registrati negli aneurismi trattati con il dispositivo WEB in 1.464 anni-paziente
  • 0% di morbilità e mortalità correlate al dispositivo nei dati di follow-up a cinque anni
  • Introduzione del sistema WEB 17 per il trattamento di aneurismi più piccoli

Terumo Neuro celebra el 15º aniversario de su WEB™ Aneurysm Embolization System, un dispositivo revolucionario que ha transformado el tratamiento de los aneurismas de bifurcación de cuello ancho. Desde su aprobación CE y lanzamiento comercial en octubre de 2010, se han implantado más de 25,000 dispositivos en todo el mundo.

El dispositivo WEB, como el primer disruptor de flujo intrasacular del mundo, ofrece una solución de un solo dispositivo que minimiza la necesidad de terapia antiplaquetaria dual. Su éxito clínico está respaldado por siete estudios globales de Buenas Prácticas Clínicas y más de 200 publicaciones revisadas por pares.

Los logros clave incluyen:

  • Cero rebleed registrados en aneurismas tratados con el dispositivo WEB durante 1,464 años-paciente
  • 0% de morbilidad y mortalidad relacionada con el dispositivo en datos de seguimiento a cinco años
  • Introducción del sistema WEB 17 para el tratamiento de aneurismas más pequeños

테루모 뉴로WEB™ 동맥류 색전술 시스템의 15주년을 기념합니다. 이 혁신적인 장치는 넓은 목의 분기 동맥류 치료를 혁신적으로 변화시켰습니다. 2010년 10월 CE 마크 승인 및 상업 출시 이후, 전 세계적으로 25,000개 이상의 장치가 이식되었습니다.

WEB 장치는 세계 최초의 내낭 흐름 방해 장치로, 이중 항혈소판 요법의 필요성을 최소화하는 단일 장치 솔루션을 제공합니다. 그 임상적 성공은 7개의 글로벌 좋은 임상 관행 연구와 200편 이상의 동료 검토 출판물에 의해 뒷받침됩니다.

주요 성과는 다음과 같습니다:

  • 1,464 환자-년 동안 WEB 장치로 치료된 동맥류에서 기록된 재출혈 제로
  • 5년 추적 데이터에서 장치 관련 이환율 및 사망률 0%
  • 더 작은 동맥류 치료를 위한 WEB 17 시스템 도입

Terumo Neuro célèbre le 15e anniversaire de son WEB™ Système d'Embolisation des Aneurysmes, un dispositif révolutionnaire qui a transformé le traitement des aneurysmes à bifurcation à col large. Depuis son approbation CE et son lancement commercial en octobre 2010, plus de 25 000 dispositifs ont été implantés dans le monde entier.

Le dispositif WEB, en tant que premier perturbateur de flux intrasacculaire au monde, offre une solution à un seul dispositif qui minimise le besoin d'une thérapie antiplaquettaire double. Son succès clinique est soutenu par sept études mondiales de Bonnes Pratiques Cliniques et plus de 200 publications évaluées par des pairs.

Les réalisations clés comprennent:

  • Zéro rebleeding enregistré dans les aneurysmes traités avec le dispositif WEB sur 1 464 années-patients
  • 0 % de morbidité et de mortalité liées au dispositif dans les données de suivi à cinq ans
  • Introduction du système WEB 17 pour le traitement des aneurysmes plus petits

Terumo Neuro feiert den 15. Jahrestag seines WEB™ Aneurysm Embolization System, eines revolutionären Geräts, das die Behandlung von breiten Halsbifurkationsaneurysmen transformiert hat. Seit seiner CE-Zertifizierung und Markteinführung im Oktober 2010 wurden weltweit über 25.000 Geräte implantiert.

Das WEB-Gerät, als weltweit erster intrasakkulärer Flussstörer, bietet eine Einheitslösung, die den Bedarf an einer dualen Thrombozytenaggregationshemmung minimiert. Sein klinischer Erfolg wird durch sieben globale Studien zur Guten Klinischen Praxis und über 200 peer-reviewed Publikationen unterstützt.

Wichtige Erfolge umfassen:

  • Null aufgezeichnete Reblutungen bei mit dem WEB-Gerät behandelten Aneurysmen über 1.464 Patientenjahre
  • 0% gerätebezogene Morbidität und Mortalität in den Fünf-Jahres-Folgedaten
  • Einführung des WEB 17-Systems zur Behandlung kleinerer Aneurysmen

Positive
  • None.
Negative
  • None.

More than 25,000 Devices Implanted Worldwide from 2010-20251

ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEB™ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.

The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.

Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."

Transforming Aneurysm Treatment with the WEB Device

The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:

  • Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
  • Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
  • Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.

The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.

About Terumo Neuro (Formerly MicroVention, Inc.)

We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEB™ Embolization System | Terumo Neuro

*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.

References:

  1. Data on file, Terumo Neuro.
  2. Pierot L, Moret J, Barreau X, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series. J Neurointerv Surg. 2018;10(6):553-559.
  3. Arthur AS, Molyneux A, Coon AL, et al. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg. 2019;11(9):924-930.
  4. Pierot L, Moret J, Turjman F, Herbreteau D, et al. WEB Treatment of Intracranial Aneurysms: Clinical and Anatomic Results in the French Observatory. AJNR. 2016.
  5. Spelle, L., et al. (2022) "Clinical Assessment of WEB device in Ruptured Aneurysms (CLARYS): 12-month angiographic results of a multicenter study." J NeuroIntervent Surg.
  6. Spelle, L., et al. (2024) "Clinical Evaluation of WEB 17 device in intracranial aneurysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms." J NeuroIntervent Surg.
  7. Pierot L, Szikora I, Barreau X, et al. Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series: 5-year follow-up. J Neurointerv Surg. 2023;15(6):552-557. 
  8. Fiorella D, Molyneux A, Coon A, et al. Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular. Therapy study (WEB-IT). J Neurointerv Surg. 2023;15(12):1175-1180. 
  9. Rai AT, Turner RC, Brotman RG, Boo S. Comparison of operating room variables, radiation exposure and implant costs for WEB versus stent assisted coiling for treatment of wide neck bifurcation aneurysms. Interv Neuroradiol. 2021;27(4):465-472.

WEB™ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25

Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-neuro-celebrates-15-years-of-the-web-device-a-game-changing-innovation-in-aneurysm-treatment-302405272.html

SOURCE Terumo Neuro

FAQ

How many WEB devices has Terumo Neuro implanted worldwide since 2010?

Over 25,000 WEB devices have been implanted worldwide from 2010-2025.

What are the key clinical outcomes of the WEB device for aneurysm treatment?

The device shows zero recorded rebleeds across 1,464 patient-years and 0% device-related morbidity and mortality in five-year follow-up studies.

When did Terumo Neuro's WEB device receive CE Mark approval?

The WEB device received CE Mark approval and was commercially launched in October 2010.

How many clinical studies and publications support the WEB device's effectiveness?

The WEB device is supported by seven global Good Clinical Practice studies and over 200 peer-reviewed publications.

What advantage does the WEB device offer over traditional aneurysm treatments?

As an intrasaccular flow disruptor, it offers a single-device solution that minimizes the need for dual antiplatelet therapy, unlike traditional treatments requiring stents and coils.
Terumo Corp

OTC:TRUMY

TRUMY Rankings

TRUMY Latest News

TRUMY Stock Data

27.54B
1.47B
0.02%
Medical Instruments & Supplies
Healthcare
Link
Japan
Tokyo